到定量噴霧吸入器 (MDI) :2020年預測
Metered Dose Inhalers to 2022
|出版商||Greystone Research Associates||商品編碼||338588|
|到定量噴霧吸入器 (MDI) :2020年預測 Metered Dose Inhalers to 2022|
|出版日期: 2015年09月01日||內容資訊: 英文||
本報告提供定量噴霧吸入器 (MDI) 市場相關調查分析、市場趨勢、技術要素、性能要素、產品評估與分析、治療藥市場分析、市場資料與預測、市場要素、主要企業等相關的系統性資訊。
Metered dose inhalers have been around for more than thirty years, and while the underlying technology is relatively straightforward and mature, device developers and their inhaled drug partners have been able to add improvements and/or new features that address MDI limitations and advance ease-of-use. Because of the underlying physiology of the human respiratory system, inhaled drug pharmacodynamics, and marked variations in the use of inhalers across patient populations, inhaler design presents unique challenges to device developers. Recent improvements in the control of the inspiry event have reduced the need for add-on devices designed to help regulate patient administration. Growth in upper airway therapeutics will help to push MDI unit demand to high single digits between now and the end of the decade.
The value we provide to our clients and subscribers is best illustrated by our ability to consistently provide strategic direction and market knowledge that contributes to their tactical and strategic decision process.
A longer life span is expected to translate to a growing number of patients diagnosed with chronic conditions. To counteract the financial and medical infrastructure implications of this trend, pressure from the public sector and managed care organizations will place a premium on therapeutic self-administration, an expectation that is creating an increased interest in routes of administration that are patient-friendly and cost-effective. Pharma company decision makers have come to the realization that for many products, success no longer only depends on the medication itself but also on achieving a consumer-compatible form of packaging and application.
As technology and products evolve, the level of precision in management decisions required to enable effective company performance is increasing. Such precision cannot be achieved without timely and accurate data about the company's macroscopic operating environment. The information that you and your management team require to execute your business and market strategies is unique to your organization and business model. This is why - in addition to the multi-client reports you will find on our site - we offer client-specific research services that start with customer-defined needs and culminate in assessments and analysis that answer the questions that represent risk to your business strategy. To discuss Greystone's Customer Defined Research services, we invite you to contact us.
‘The pediatric market is an important segment for URT therapeutics. In 2013, 9% of children in the United States were considered asthmatic. Nine million U.S. children under 18 have been diagnosed with asthma at some point in their lifetime. Approximately 40% of children who have asthmatic parents will develop asthma. Because of potential side effects, regulatory approval and prescribing options for pediatric asthma pose unique challenges for drug developers and caregivers.’